Comparative Study of Two Corneal Graft Storage Media: New Animal Compound Free Medium Versus Reference Medium

Sponsor
Centre Hospitalier Universitaire de Saint Etienne (Other)
Overall Status
Completed
CT.gov ID
NCT01694914
Collaborator
Ministry of Health, France (Other)
122
4
2
25
30.5
1.2

Study Details

Study Description

Brief Summary

At present, all commercially available corneal organ culture media contain foetal calf serum (FCS) and sometimes other compounds extracted from animals. These compounds are necessary for corneal cell survival but are problematic because they theoretically have risk of anthropozoonosis transmission, especially for new variant of CJD and the variability between FCS batches influence graft quality. Our laboratory research allowed in vitro and ex vivo validation of a new medium free compound animal. We proved its superiority over conventional medium containing 2% FCS for endothelial cell survival during the storage time. The goal of this clinical trial is now to assess its superiority in patients.

Condition or Disease Intervention/Treatment Phase
  • Procedure: corneal graft
Phase 3

Study Design

Study Type:
Interventional
Actual Enrollment :
122 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Comparative Study of Two Corneal Graft Storage Media: New Animal Compound Free Medium Versus Reference Medium
Study Start Date :
Jan 1, 2012
Actual Primary Completion Date :
Feb 1, 2014
Actual Study Completion Date :
Feb 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Experimental: Animal Compound Free Medium

Patients in this arm receive a corneal graft stored in organ culture in a animal compound free medium

Procedure: corneal graft

Active Comparator: organ culture medium containing 2% of fœtal calf serum

Patients in this arm receive a corneal graft stored in organ culture in a commercial organ culture medium containing 2% of fœtal calf serum

Procedure: corneal graft

Outcome Measures

Primary Outcome Measures

  1. the primary outcome is the endothelial cell density (ECD) of the corneal grafts. [one year after graft]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Male and female patients

  • over 18 years of age

  • Clinically proven corneal disease

  • Registered on the French National waiting list (GLAC)

  • Patient informed consent

  • Patient who needs a 8.25mm of diameter perforating keratoplasty, either isolated or combined with lens surgery

  • Low immune rejection risk (< 2 quadrants of neovascularization, no previous history of herpetic keratitis nor graft rejection)

  • No previous history of glaucoma or elevated intra ocular pressure (>22 mm

Exclusion Criteria:
  • Patient is unlikely to comply with the requirements of the protocol

Contacts and Locations

Locations

Site City State Country Postal Code
1 CHU Besançon Besancon France 25000
2 CHU Clermont-Ferrand Clermont-Ferrand France 63003
3 CHU Grenoble Grenoble France 38043
4 CHU Saint-Etienne Saint-Etienne France 42055

Sponsors and Collaborators

  • Centre Hospitalier Universitaire de Saint Etienne
  • Ministry of Health, France

Investigators

  • Principal Investigator: Gilles Thuret, MD-PhD, CHU Saint-Etienne

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier Universitaire de Saint Etienne
ClinicalTrials.gov Identifier:
NCT01694914
Other Study ID Numbers:
  • 0908018
  • 2010-A00234-35
First Posted:
Sep 27, 2012
Last Update Posted:
Jan 30, 2015
Last Verified:
Jan 1, 2015
Keywords provided by Centre Hospitalier Universitaire de Saint Etienne

Study Results

No Results Posted as of Jan 30, 2015